[go: up one dir, main page]

MX2018010971A - Compuestos y métodos para modular la tirosina cinasa de bruton. - Google Patents

Compuestos y métodos para modular la tirosina cinasa de bruton.

Info

Publication number
MX2018010971A
MX2018010971A MX2018010971A MX2018010971A MX2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A
Authority
MX
Mexico
Prior art keywords
modulating
compounds
methods
bruton
tyrosine kinase
Prior art date
Application number
MX2018010971A
Other languages
English (en)
Other versions
MX388026B (es
Inventor
A Miller Richard
Verner Erik
Hudson Ryan
- Marie Beausoleil Anne
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of MX2018010971A publication Critical patent/MX2018010971A/es
Publication of MX388026B publication Critical patent/MX388026B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

En la presente se proporcionan, entre otros, compuestos y métodos para modular la tirosina cinasa de Bruton.
MX2018010971A 2016-03-11 2017-03-10 Compuestos y métodos para modular la tirosina cinasa de bruton. MX388026B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307399P 2016-03-11 2016-03-11
US201662342004P 2016-05-26 2016-05-26
PCT/US2017/021966 WO2017156495A1 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
MX2018010971A true MX2018010971A (es) 2019-03-28
MX388026B MX388026B (es) 2025-03-19

Family

ID=59789888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010971A MX388026B (es) 2016-03-11 2017-03-10 Compuestos y métodos para modular la tirosina cinasa de bruton.

Country Status (13)

Country Link
US (2) US10870652B2 (es)
EP (1) EP3426637B1 (es)
JP (1) JP6972002B2 (es)
KR (1) KR102416971B1 (es)
CN (2) CN115746000A (es)
AU (1) AU2017230098B2 (es)
CA (1) CA3017567A1 (es)
ES (1) ES2912465T3 (es)
IL (1) IL261583A (es)
MX (1) MX388026B (es)
PL (1) PL3426637T3 (es)
WO (1) WO2017156495A1 (es)
ZA (1) ZA201805951B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554118B2 (en) 2017-03-22 2023-01-17 Xibin Liao Bruton's tyrosine kinase inhibitors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3017567A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
AU2020281410A1 (en) * 2019-05-31 2021-10-07 Haisco Pharmaceuticals Pte. Ltd. BTK inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
JP7213604B2 (ja) * 2019-09-26 2023-01-27 ジャンボ ドラッグ バンク カンパニー リミテッド 選択的ｂｔｋキナーゼ阻害剤としてのピラゾロピリジン系化合物
CN114437078A (zh) * 2020-11-03 2022-05-06 海思科医药集团股份有限公司 一种降解btk的氘代物及其在医药上的应用
WO2022253250A1 (zh) * 2021-06-01 2022-12-08 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
TW202321191A (zh) * 2021-07-29 2023-06-01 美商賽迪拉治療股份有限公司 Ｔｅａｄ抑制劑及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE467620T1 (de) 1999-03-26 2010-05-15 Euro Celtique Sa Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
NZ569087A (en) * 2005-12-13 2011-09-30 Schering Corp Polycyclic indazole derivatives that are ERK inhibitors
JP2009528991A (ja) * 2006-02-14 2009-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なピロロ（３，２−ｃ）ピリジン
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) * 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
MX2011000661A (es) * 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
JP5613671B2 (ja) 2008-09-16 2014-10-29 プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． 新規化合物ｉｉ
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
PH12014500122A1 (en) * 2011-07-13 2014-03-24 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9458162B2 (en) 2012-01-31 2016-10-04 Nanjing Allgen Pharma Co. Ltd. Cyclic molecules as bruton's tyrosine kinase inhibitors
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
US10358446B2 (en) * 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
EA201891626A1 (ru) * 2016-01-21 2019-04-30 Зибо Биополар Чангшенг Фармасьютикал Ко. Лтд. Ингибиторы тирозинкиназы брутона
CA3017567A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554118B2 (en) 2017-03-22 2023-01-17 Xibin Liao Bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CN115746000A (zh) 2023-03-07
PL3426637T3 (pl) 2022-05-30
WO2017156495A8 (en) 2018-09-27
KR102416971B1 (ko) 2022-07-04
AU2017230098A1 (en) 2018-09-20
EP3426637A1 (en) 2019-01-16
CA3017567A1 (en) 2017-09-14
ZA201805951B (en) 2020-12-23
AU2017230098B2 (en) 2021-03-25
ES2912465T3 (es) 2022-05-26
US10870652B2 (en) 2020-12-22
CN109071455B (zh) 2022-08-02
EP3426637B1 (en) 2022-02-09
EP3426637A4 (en) 2019-09-18
WO2017156495A1 (en) 2017-09-14
US11306099B1 (en) 2022-04-19
KR20180133415A (ko) 2018-12-14
MX388026B (es) 2025-03-19
JP6972002B2 (ja) 2021-11-24
CN109071455A (zh) 2018-12-21
NZ745927A (en) 2024-05-31
JP2019507793A (ja) 2019-03-22
IL261583A (en) 2018-10-31
US20190106423A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
MX392031B (es) Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2
CO2020006248A2 (es) Moduladores de la vía de estrés integrada
CO2018012946A2 (es) Moduladores de la vía de estrés integrada
CO2020006227A2 (es) Moduladores de la vía de estrés integrada
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2020001302A (es) Procesos para preparar compuestos de pirrolidina.
UY37230A (es) Moduladores de la vía de estrés integrada
UY37231A (es) Moduladores de la vía de estrés integrada
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
UY37958A (es) Moduladores de la vía de estrés integrada
UY37229A (es) Moduladores de la vía de estrés integrada
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
MX384833B (es) Inhibidores de tirosina quinasa de bruton
MX2016009862A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
CL2020001264A1 (es) Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide.
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
MY210476A (en) Vitamin d pediatric dosage forms, methods of making and using
MX2018014771A (es) Oligonucleotidos que comprenden nucleosidos modificados.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201991488A1 (ru) Модуляторы калиевых каналов
EA201891504A1 (ru) Гербицидная комбинация